€0.21
Your prediction
Financial data and news for Recce Pharmaceuticals Ltd.
sharewise wants to provide you with the best news and tools for Recce Pharmaceuticals Ltd., so we directly link to the best financial data sources.
Financials
News
RECCE® 327 Topical Gel Highly Effective and Accelerated Wound Healing for Burn Wounds in Rat Infection Models
Highlights:
- RECCE® 327 Topical Gel (R327G) highly effective against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infected burn wounds (in-vivo)
-
Recce Pharmaceuticals Enters into DTRA-Backed Cooperative Research & Development Agreement with USAMRIID
Highlights:
- Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the United States’
Patient Dosing and Multiple Sites Activated in Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia
Highlights:
- Patient dosing is underway for Registrational Phase 3 Clinical Trial for Diabetic Foot Infections (DFI), with five (5) clinical study sites now activated across one
Placement of Entitlement Offer Shortfall
Highlights:
- Entitlement Offer Shortfall of approximately 26.4 million shares placed to existing institutional and sophisticated investors raising A$7.4 million
-
China Patent Accepted for RECCE® Anti-Infectives
Sydney Australia, 26 May 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to
Phase II Clinical Trial Receives Additional Approval for Treating Diabetic Patients with RECCE® 327 Topical Gel
Highlights:
- Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing